Head-To-Head Review: Evaxion Biotech A/S (NASDAQ:EVAX) versus Cardiol Therapeutics (NASDAQ:CRDL)

Cardiol Therapeutics (NASDAQ:CRDL) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Earnings and Valuation

This table compares Cardiol Therapeutics and Evaxion Biotech A/S”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	$60,000.00	2,570.12	-$20.84 million	($0.33)	-5.85
Evaxion Biotech A/S	$70,000.00	204.87	-$22.12 million	($0.29)	-8.86

Cardiol Therapeutics has higher earnings, but lower revenue than Evaxion Biotech A/S. Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cardiol Therapeutics and Evaxion Biotech A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-118.65%	-85.28%
Evaxion Biotech A/S	-347.83%	N/A	-79.40%

Insider and Institutional Ownership

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Cardiol Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Cardiol Therapeutics and Evaxion Biotech A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	0	0	4	1	3.20
Evaxion Biotech A/S	0	0	2	0	3.00

Cardiol Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 353.37%. Evaxion Biotech A/S has a consensus price target of $11.00, suggesting a potential upside of 328.02%. Given Cardiol Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than Evaxion Biotech A/S.

Summary

Cardiol Therapeutics beats Evaxion Biotech A/S on 10 of the 15 factors compared between the two stocks.

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.